The FDA response to the request for the ODD and Rare Ped
The FDA response to the request for the ODD and Rare Ped Disease Designation should be coming soon- it could really come any day now- it's been over 4 months. The last ODD they received took a little less than 4 months to get from the FDA. It will be very interesting to see how the market reacts if it is approved. I don't think this company has had any substantive good news in a year.
One theory is if they do end up spinning off ESS in some way, there is probably a good possibility that the RPDD would be included so maybe they are waiting for FDA's response?
2
Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Albion Enterprise VCT PLC Enhances Its Equity Portfolio Albion Enterprise VCT PLC (LSE: AAEV) has recently made a significant move to bolster its equity by issuing new shares. This decision aligns with the company’s commitment to expanding its capital while providing opportunities for shareholders through its Dividend Reinvestment Scheme. Details of the New Share...
Continue Reading
Capsida's Recent Advances in Genetic Medicine Capsida Biotherapeutics has made a remarkable stride by partnering with AbbVie to combat neurodegenerative diseases, a step that marks a significant achievement in the realm of genetic medicine. The collaboration has evolved, leading to AbbVie exercising its option on the first neurodegenerative disease program, which...
Continue Reading
AB Amber Grid's 2024 Operating Results Overview AB Amber Grid has published its unaudited financial results for the year 2024, reflecting the company’s performance in accordance with the International Financial Reporting Standards. With a focus on strategic growth, the company demonstrated robust management despite challenges in the market. Financial Performance...
Continue Reading
Linkage Global Inc. Closes $1 Million Private Placement Financing Linkage Global Inc (NASDAQ: LGCB), a leading cross-border e-commerce service provider based in Japan, has successfully completed a private placement financing that raised $1 million. This announcement marks a significant milestone for the company as it continues to enhance its financial foundation. Details...
Continue Reading
Understanding the Amedisys and UnitedHealth Merger Situation Amedisys Inc (NASDAQ: AMED) has seen its shares rise as the company announces an extension to its merger deadline with UnitedHealth Group Incorporated (NYSE: UNH). This unexpected turn of events has grabbed the attention of investors and industry watchers alike. What Is the Merger About? The proposed merger...
Continue Reading
